Flora Growth Corp. (FLGC)
USD 0.63
(5.0%)
USD 0.63
(5.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 17.22 Million USD | -29.92% |
| 2022 | 24.57 Million USD | 187.83% |
| 2021 | 8.53 Million USD | 166.65% |
| 2020 | 3.2 Million USD | 29.21% |
| 2019 | 2.47 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 21.13 Million USD | 22.73% |
| 2024 Q2 | 21.81 Million USD | 3.19% |
| 2023 FY | 17.22 Million USD | -29.92% |
| 2023 Q3 | 18.47 Million USD | -8.76% |
| 2023 Q1 | 23.42 Million USD | -4.67% |
| 2023 Q4 | 17.22 Million USD | -6.8% |
| 2023 Q2 | 20.25 Million USD | -13.56% |
| 2022 Q4 | 24.57 Million USD | 29.56% |
| 2022 Q3 | 18.96 Million USD | 14.27% |
| 2022 Q1 | - USD | -100.0% |
| 2022 Q2 | 16.59 Million USD | 0.0% |
| 2022 FY | 24.57 Million USD | 187.83% |
| 2021 Q1 | - USD | -100.0% |
| 2021 FY | 8.53 Million USD | 166.65% |
| 2021 Q2 | 6.21 Million USD | 0.0% |
| 2021 Q4 | 8.53 Million USD | 0.0% |
| 2020 Q4 | 3.2 Million USD | 0.0% |
| 2020 Q3 | 3.2 Million USD | 109.01% |
| 2020 Q2 | 1.53 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 3.2 Million USD | 29.21% |
| 2019 FY | 2.47 Million USD | 0.0% |
| 2019 Q2 | 414.08 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | 82.54% |
| Safety Shot Inc | 3.89 Million USD | -342.492% |
| Biofrontera Inc. | 23.13 Million USD | 25.572% |
| DURECT Corporation | 30.4 Million USD | 43.36% |
| Cosmos Health Inc. | 30.25 Million USD | 43.073% |
| Cronos Group Inc. | 43.73 Million USD | 60.623% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 97.394% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 97.893% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 64.45% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 17.905% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 90.504% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -25.211% |
| ProPhase Labs, Inc. | 42.54 Million USD | 59.52% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -180.507% |
| Alpha Teknova, Inc. | 38.55 Million USD | 55.327% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 87.417% |
| SCYNEXIS, Inc. | 55.45 Million USD | 68.941% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 96.349% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -96.688% |
| Dynavax Technologies Corporation | 375.02 Million USD | 95.408% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 89.493% |
| SIGA Technologies, Inc. | 57.97 Million USD | 70.295% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 92.165% |
| Shineco, Inc. | 47.6 Million USD | 63.821% |
| Indivior PLC | 1.95 Billion USD | 99.117% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -7745.585% |
| Radius Health, Inc. | 804.29 Million USD | 97.859% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -180.507% |
| Incannex Healthcare Limited | 5.83 Million USD | -195.403% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -87.265% |
| Alimera Sciences, Inc. | 107.35 Million USD | 83.958% |
| Silver Spike Investment Corp. | 3 Million USD | -472.192% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -808.35% |
| Alvotech | 1.88 Billion USD | 99.085% |
| Journey Medical Corporation | 56.49 Million USD | 69.518% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 19.205% |
| Embecta Corp. | 2.03 Billion USD | 99.154% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -102.838% |
| Procaps Group, S.A. | 462.06 Million USD | 96.273% |
| PainReform Ltd. | 2.69 Million USD | -539.985% |
| Harrow Health, Inc. | 241.75 Million USD | 92.876% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 96.467% |
| OptiNose, Inc. | 194.33 Million USD | 91.138% |
| Kamada Ltd. | 109.96 Million USD | 84.339% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 67.206% |
| Phibro Animal Health Corporation | 725.54 Million USD | 97.626% |
| Procaps Group S.A. | 462.06 Million USD | 96.273% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -22.821% |
| Talphera, Inc. | 6.29 Million USD | -173.8% |
| Viatris Inc. | 27.21 Billion USD | 99.937% |
| Rockwell Medical, Inc. | 30.88 Million USD | 44.233% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 80.945% |
| Tilray Brands, Inc. | 892.11 Million USD | 98.07% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 98.183% |
| PetIQ, Inc. | 645.22 Million USD | 97.331% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 98.311% |
| Assertio Holdings, Inc. | 148.41 Million USD | 88.396% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 97.938% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 90.067% |
| Hempacco Co., Inc. | 18.82 Million USD | 8.503% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 97.555% |
| Alvotech | 1.88 Billion USD | 99.085% |
| Currenc Group, Inc. | 177.67 Million USD | 90.307% |
| Evoke Pharma, Inc. | 9.64 Million USD | -78.502% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -102.838% |
| Evolus, Inc. | 209.68 Million USD | 91.787% |
| HUTCHMED (China) Limited | 536.38 Million USD | 96.789% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 98.028% |
| Akanda Corp. | 12.66 Million USD | -35.939% |